TC
ACRS icon

TFS Capital’s Aclaris Therapeutics ACRS Stock Holding History

TFS Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-33,223
Closed -$614K – 730
2016
Q2 		$614K Buy
+33,223
New +$658K 0.11% 322

Other funds holding ACRS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TFS Capital's ACRS Position: Q3 2016 in Review

TFS Capital sold out of Aclaris Therapeutics (ACRS) in Q3 2016, closing a stake of 33,223 shares — an estimated $614K sold.

TFS Capital first reported a position in ACRS in Q2 2016 and held it in 1 quarter. The position peaked at $614K in Q2 2016. 58 funds tracked by Wall St. Rank hold ACRS as of Q3 2016.

  • TFS Capital reported no remaining Aclaris Therapeutics position as of Q3 2016 after selling out during the quarter.
  • TFS Capital sold 33,223 Aclaris Therapeutics shares in Q3 2016, an estimated $614K.
  • TFS Capital first reported a position in Aclaris Therapeutics in Q2 2016 and held it in 1 quarter.
  • TFS Capital's Aclaris Therapeutics position peaked at $614K in Q2 2016.
  • 58 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2016.

Based on TFS Capital's 13F filing for Q3 2016, filed 10 Nov 2016.